Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Ambu A/S (AMBU-B.CO)
Ballerup, DK
Established in 1937 and headquartered in Ballerup, Denmark, Ambu A/S is a global medical technology company specializing in the design, manufacture, and sale of advanced medical devices. The company serves hospitals, clinics, and emergency services worldwide, providing essential healthcare solutions across key disciplines such as visualization, anesthesia, and patient monitoring and diagnostics. Their extensive product portfolio includes sophisticated endoscopy equipment like bronchoscopes and dedicated monitors. For neurology, Ambu offers EEG and EMG electrodes, as well as tools for EMG-guided injections and intraoperative monitoring systems. Cardiology solutions feature ECG electrodes. A substantial portion of their offerings is dedicated to airway management and anesthesia, comprising specialized bronchoscopes, video laryngoscopes, various intubation tubes (double and single lumen), endobronchial blockers, laryngeal and face masks, breathing bags, and resuscitation devices. Additionally, Ambu provides critical emergency and training products, including extrication collars, CPR breathing barriers, and training manikins.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.97% | -1.84% | -6.35% | -26.20% | -28.49% | -28.99% | -40.82% | -45.80% | -73.67% | +21.53% | +5,678.30% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 5 | 0 |
| Hold | 3 | +1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+12.0% ★ Q1'26: +1.2% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+159.1% ★ Q1'26: -36.6% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+9.6% ★ Q1'26: +12.6% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+13.0% ★ Q1'26: +11.0% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+11.1% ★ Q1'26: +8.9% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%0.0% ★ Q1'26: +0.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.47× Q1'26: 0.51× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Sep 2015 actual |
Sep 2016 actual |
Sep 2017 actual |
Sep 2018 actual |
Sep 2019 actual |
Sep 2020 actual |
Sep 2021 actual |
Sep 2022 actual |
Sep 2023 actual |
Sep 2024 actual |
Sep 2025 actual |
Sep 2026 8 Rev. Ana. 6 EPS Ana. |
Sep 2027 8 Rev. Ana. 7 EPS Ana. |
Sep 2028 8 Rev. Ana. 7 EPS Ana. |
Sep 2029 4 Rev. Ana. 2 EPS Ana. |
Sep 2030 4 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.89B
est: 1.88B (+0.2%)
|
2.08B
est: 2.10B (-0.6%)
|
2.36B
est: 2.37B (-0.7%)
|
2.61B
est: 2.61B (-0.2%)
|
2.82B
est: 2.83B (-0.2%)
|
3.57B
est: 3.57B (-0.2%)
|
4.01B
est: 4.03B (-0.4%)
|
4.44B
est: 4.44B (+0.0%)
|
4.78B
est: 5.08B (-5.9%)
|
5.39B
est: 5.42B (-0.5%)
|
6.04B
est: 6.08B (-0.7%)
|
6.47B
6.42B – 6.59B
+6.5% YoY
|
7.22B
7.12B – 7.38B
+11.5% YoY
|
8.04B
8.03B – 8.06B
+11.4% YoY
|
8.91B
8.81B – 9.09B
+10.8% YoY
|
9.92B
9.81B – 10.12B
+11.3% YoY
|
| EBITDA |
340.00M
est: 242.94M (+39.9%)
|
456.00M
est: 270.19M (+68.8%)
|
531.00M
est: 305.76M (+73.7%)
|
616.00M
est: 336.47M (+83.1%)
|
608.00M
est: 364.36M (+66.9%)
|
599.00M
est: 460.73M (+30.0%)
|
494.00M
est: 519.38M (-4.9%)
|
442.00M
est: 572.61M (-22.8%)
|
601.00M
est: 678.28M (-11.4%)
|
691.00M
est: 724.16M (-4.6%)
|
1.16B
est: 812.31M (+42.4%)
|
865.11M
857.68M – 880.86M
+6.5% YoY
|
964.93M
951.97M – 985.94M
+11.5% YoY
|
1.08B
1.07B – 1.08B
+11.4% YoY
|
1.19B
1.18B – 1.22B
+10.8% YoY
|
1.33B
1.31B – 1.35B
+11.3% YoY
|
| EBIT |
244.00M
est: 132.82M (+83.7%)
|
358.00M
est: 147.71M (+142.4%)
|
427.00M
est: 167.16M (+155.4%)
|
496.00M
est: 183.94M (+169.6%)
|
433.00M
est: 199.19M (+117.4%)
|
428.00M
est: 251.88M (+69.9%)
|
334.00M
est: 283.94M (+17.6%)
|
141.00M
est: 313.04M (-55.0%)
|
271.00M
est: 367.84M (-26.3%)
|
327.00M
est: 392.72M (-16.7%)
|
785.00M
est: 440.52M (+78.2%)
|
469.16M
465.13M – 477.70M
+6.5% YoY
|
523.29M
516.26M – 534.69M
+11.5% YoY
|
583.06M
582.20M – 583.93M
+11.4% YoY
|
646.05M
638.84M – 659.02M
+10.8% YoY
|
718.93M
710.91M – 733.37M
+11.3% YoY
|
| Net Income |
152.00M
est: 192.99M (-21.2%)
|
250.00M
est: 296.07M (-15.6%)
|
301.00M
est: 378.49M (-20.5%)
|
337.00M
est: 383.77M (-12.2%)
|
317.00M
est: 393.95M (-19.5%)
|
241.00M
est: 281.06M (-14.3%)
|
247.00M
est: 275.79M (-10.4%)
|
93.00M
est: 200.82M (-53.7%)
|
168.00M
est: 367.00M (-54.2%)
|
235.00M
est: 511.12M (-54.0%)
|
609.00M
est: 643.38M (-5.3%)
|
591.13M
589.36M – 653.95M
-8.1% YoY
|
821.00M
802.83M – 917.88M
+38.9% YoY
|
1.07B
991.78M – 1.24B
+30.2% YoY
|
1.33B
1.31B – 1.36B
+24.3% YoY
|
1.65B
1.63B – 1.70B
+24.5% YoY
|
| SGA |
621.00M
est: 859.43M (-27.7%)
|
702.00M
est: 955.80M (-26.6%)
|
795.00M
est: 1.08B (-26.5%)
|
873.00M
est: 1.19B (-26.7%)
|
1.05B
est: 1.29B (-18.2%)
|
1.63B
est: 1.63B (-0.2%)
|
1.94B
est: 1.84B (+5.5%)
|
2.15B
est: 2.03B (+6.2%)
|
2.12B
est: 2.26B (-6.6%)
|
2.23B
est: 2.42B (-7.7%)
|
2.46B
est: 2.71B (-9.4%)
|
2.89B
2.86B – 2.94B
+6.5% YoY
|
3.22B
3.18B – 3.29B
+11.5% YoY
|
3.59B
3.58B – 3.59B
+11.4% YoY
|
3.98B
3.93B – 4.06B
+10.8% YoY
|
4.43B
4.38B – 4.51B
+11.3% YoY
|
| EPS |
0.63
est: 0.72 (-12.8%)
|
1.05
est: 1.11 (-5.3%)
|
1.27
est: 1.42 (-10.4%)
|
1.39
est: 1.44 (-3.3%)
|
1.30
est: 1.48 (-11.9%)
|
0.98
est: 1.05 (-6.9%)
|
0.98
est: 1.03 (-5.1%)
|
0.37
est: 0.75 (-50.8%)
|
0.65
est: 1.36 (-52.2%)
|
0.88
est: 1.90 (-53.8%)
|
2.29
est: 2.40 (-4.4%)
|
2.33
2.21 – 2.45
-2.6% YoY
|
3.20
3.01 – 3.44
+37.3% YoY
|
4.18
3.71 – 4.64
+30.5% YoY
|
4.98
4.90 – 5.11
+19.1% YoY
|
6.20
6.11 – 6.36
+24.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-05 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-04 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI Denmark ETF EDEN | 0.78% | 1.61M | 0.53% |
| 2 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Acc CEM.PA | 0.13% | 431.7K | 0.23% |
| 3 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Dist X026.DE | 0.13% | 431.7K | 0.23% |
| 4 | iShares MSCI Europe Small-Cap ETF IEUS | 0.12% | 215.2K | 0.41% |
| 5 | Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L | 0.11% | 3.84M | 0.30% |
| 6 | iShares Currency Hedged MSCI EAFE Small-Cap ETF HSCZ | 0.05% | 122.4K | 0.83% |
| 7 | iShares MSCI EAFE Small-Cap ETF SCZ | 0.05% | 7.37M | 0.40% |
| 8 | Dimensional - International Small Cap ETF DFIS | 0.05% | 2.94M | 0.39% |
| 9 | State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR Acc ZPRX.DE | 0.05% | 361.6K | 0.30% |
| 10 | WisdomTree International Equity Fund DWM | 0.04% | 261.3K | 0.48% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Britt Meelby Jensen | Chief Executive Officer | 13M | female |
| Henrik Skak Bender | Chief Financial Officer | 6M | male |
| Thomas Lykke Henriksen | Head of HR Systems | 72.0K | male |
| Holger Hesse | Founder | — | — |
| Jesper Johnsen Steen | Chief Marketing Officer | — | male |
| Sanne Kjærsgaard Hjordrup | Chief People & Culture Officer | — | female |
| Anders Hjort | Head of Investor Relations | — | male |
| Tine Bjorn Schmidt | Head of Corporate Communications | — | female |
| Finn Mohring | Chief Technology Officer | — | male |
| Graziela Chaluppe dos Santos Malucelli | Chief Operations Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AMBU-B.CO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
